ENSG00000177084 |
POLE |
colorectal adenocarcinoma |
stop_gained |
7.912% (180/2275) |
3 entries |
ENSG00000177084 |
POLE |
endometrial carcinoma |
missense_variant |
8.378% (62/740) |
10 entries |
ENSG00000177084 |
POLE |
basal cell carcinoma |
missense_variant |
16.18% (11/68) |
2 entries |
ENSG00000177084 |
POLE |
cecum adenocarcinoma |
frameshift_variant |
12.32% (34/276) |
2 entries |
ENSG00000177084 |
POLE |
colon adenocarcinoma |
missense_variant |
6.855% (107/1561) |
12 entries |
ENSG00000177084 |
POLE |
colon adenocarcinoma |
stop_gained |
6.855% (107/1561) |
3 entries |
ENSG00000177084 |
POLE |
Endometrial Endometrioid Adenocarcinoma |
sequence_alteration |
6.552% (243/3709) |
2 entries |
ENSG00000177084 |
POLE |
cecum adenocarcinoma |
missense_variant |
12.32% (34/276) |
6 entries |
ENSG00000177084 |
POLE |
basal cell carcinoma |
sequence_alteration |
16.18% (11/68) |
1 entry |
ENSG00000177084 |
POLE |
Endometrial Endometrioid Adenocarcinoma |
frameshift_variant |
6.552% (243/3709) |
1 entry |
ENSG00000177084 |
POLE |
colorectal adenocarcinoma |
sequence_alteration |
7.912% (180/2275) |
3 entries |
ENSG00000177084 |
POLE |
colorectal adenocarcinoma |
conservative_inframe_deletion |
7.912% (180/2275) |
1 entry |
ENSG00000177084 |
POLE |
endometrium adenocarcinoma |
missense_variant |
53.54% (53/99) |
4 entries |
ENSG00000177084 |
POLE |
colon adenocarcinoma |
sequence_alteration |
6.855% (107/1561) |
6 entries |
ENSG00000177084 |
POLE |
Ovarian Endometrioid Adenocarcinoma |
missense_variant |
14.1% (32/227) |
3 entries |
ENSG00000177084 |
POLE |
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
6.552% (243/3709) |
10 entries |
ENSG00000177084 |
POLE |
colorectal adenocarcinoma |
missense_variant |
7.912% (180/2275) |
14 entries |
ENSG00000177084 |
POLE |
Endometrial Endometrioid Adenocarcinoma |
stop_gained |
6.552% (243/3709) |
3 entries |
ENSG00000177084 |
POLE |
colorectal adenocarcinoma |
frameshift_variant |
7.912% (180/2275) |
3 entries |
ENSG00000177084 |
POLE |
melanoma |
missense_variant |
13.1% (19/145) |
2 entries |
ENSG00000177084 |
POLE |
melanoma |
frameshift_variant |
13.1% (19/145) |
1 entry |
ENSG00000177084 |
POLE |
cecum adenocarcinoma |
sequence_alteration |
12.32% (34/276) |
1 entry |
ENSG00000177084 |
POLE |
colon adenocarcinoma |
frameshift_variant |
6.855% (107/1561) |
4 entries |
ENSG00000177084 |
POLE |
Endometrial Undifferentiated Carcinoma |
missense_variant |
8.696% (4/46) |
3 entries |
ENSG00000177084 |
POLE |
Uterine Carcinosarcoma |
sequence_alteration |
3.349% (7/209) |
1 entry |
ENSG00000177084 |
POLE |
adrenal cortex carcinoma |
missense_variant |
1.058% (2/189) |
1 entry |
ENSG00000177084 |
POLE |
colorectal adenocarcinoma |
amino_acid_insertion |
7.912% (180/2275) |
1 entry |
ENSG00000177084 |
POLE |
bladder transitional cell carcinoma |
frameshift_variant |
5.97% (28/469) |
2 entries |
ENSG00000177084 |
POLE |
gastric adenocarcinoma |
stop_gained |
3.875% (31/800) |
1 entry |
ENSG00000177084 |
POLE |
prostate adenocarcinoma |
missense_variant |
1.582% (34/2149) |
2 entries |
ENSG00000177084 |
POLE |
lung adenocarcinoma |
missense_variant |
3.073% (78/2538) |
5 entries |
ENSG00000177084 |
POLE |
gastric adenocarcinoma |
sequence_alteration |
3.875% (31/800) |
1 entry |
ENSG00000177084 |
POLE |
Uterine Carcinosarcoma |
missense_variant |
3.349% (7/209) |
3 entries |
ENSG00000177084 |
POLE |
HER2 Positive Breast Carcinoma |
missense_variant |
2.778% (3/108) |
2 entries |
ENSG00000177084 |
POLE |
leiomyosarcoma |
missense_variant |
2.0% (2/100) |
1 entry |
ENSG00000177084 |
POLE |
cervical squamous cell carcinoma |
missense_variant |
2.154% (7/325) |
1 entry |
ENSG00000177084 |
POLE |
HER2 Positive Breast Carcinoma |
sequence_alteration |
2.778% (3/108) |
1 entry |
ENSG00000177084 |
POLE |
acute myeloid leukemia |
missense_variant |
0.7931% (11/1387) |
2 entries |
ENSG00000177084 |
POLE |
rectal adenocarcinoma |
sequence_alteration |
3.551% (25/704) |
1 entry |
ENSG00000177084 |
POLE |
rectal adenocarcinoma |
frameshift_variant |
3.551% (25/704) |
1 entry |
ENSG00000177084 |
POLE |
melanoma |
sequence_alteration |
13.1% (19/145) |
1 entry |
ENSG00000177084 |
POLE |
mucosal melanoma |
missense_variant |
7.143% (5/70) |
1 entry |
ENSG00000177084 |
POLE |
non-small cell lung carcinoma |
missense_variant |
5.319% (10/188) |
2 entries |
ENSG00000177084 |
POLE |
squamous cell lung carcinoma |
missense_variant |
2.897% (27/932) |
3 entries |
ENSG00000177084 |
POLE |
papillary thyroid carcinoma |
missense_variant |
0.818% (4/489) |
1 entry |
ENSG00000177084 |
POLE |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
missense_variant |
1.136% (3/264) |
2 entries |
ENSG00000177084 |
POLE |
head and neck squamous cell carcinoma |
missense_variant |
0.9539% (6/629) |
1 entry |
ENSG00000177084 |
POLE |
rectal adenocarcinoma |
missense_variant |
3.551% (25/704) |
5 entries |
ENSG00000177084 |
POLE |
Ovarian Endometrioid Adenocarcinoma |
sequence_alteration |
14.1% (32/227) |
1 entry |
ENSG00000177084 |
POLE |
brain glioblastoma |
missense_variant |
1.092% (16/1465) |
6 entries |
ENSG00000177084 |
POLE |
pancreatic neuroendocrine tumor |
stop_gained |
2.542% (6/236) |
1 entry |
ENSG00000177084 |
POLE |
diffuse large B-cell lymphoma |
missense_variant |
1.081% (4/370) |
3 entries |
ENSG00000177084 |
POLE |
prostate adenocarcinoma |
frameshift_variant |
1.582% (34/2149) |
1 entry |
ENSG00000177084 |
POLE |
thyroid carcinoma |
missense_variant |
2.808% (26/926) |
1 entry |
ENSG00000177084 |
POLE |
urothelial carcinoma |
missense_variant |
10.47% (9/86) |
1 entry |
ENSG00000177084 |
POLE |
Endometrial Clear Cell Adenocarcinoma |
missense_variant |
3.226% (4/124) |
3 entries |
ENSG00000177084 |
POLE |
gastric adenocarcinoma |
frameshift_variant |
3.875% (31/800) |
1 entry |
ENSG00000177084 |
POLE |
bladder transitional cell carcinoma |
missense_variant |
5.97% (28/469) |
4 entries |
ENSG00000177084 |
POLE |
lung adenocarcinoma |
stop_gained |
3.073% (78/2538) |
1 entry |
ENSG00000177084 |
POLE |
osteosarcoma |
sequence_alteration |
1.316% (2/152) |
2 entries |
ENSG00000177084 |
POLE |
ovarian serous adenocarcinoma |
missense_variant |
0.2169% (2/922) |
1 entry |
ENSG00000177084 |
POLE |
bile duct adenocarcinoma |
missense_variant |
1.12% (7/625) |
2 entries |
ENSG00000177084 |
POLE |
endometrium adenocarcinoma |
sequence_alteration |
53.54% (53/99) |
1 entry |
ENSG00000177084 |
POLE |
gastric intestinal type adenocarcinoma |
missense_variant |
5.882% (5/85) |
2 entries |
ENSG00000177084 |
POLE |
gastric adenocarcinoma |
missense_variant |
3.875% (31/800) |
3 entries |
ENSG00000177084 |
POLE |
breast ductal adenocarcinoma |
sequence_alteration |
2.868% (46/1604) |
2 entries |
ENSG00000177084 |
POLE |
Gallbladder Adenocarcinoma |
missense_variant |
1.031% (2/194) |
1 entry |
ENSG00000177084 |
POLE |
colon adenocarcinoma |
conservative_inframe_deletion |
6.855% (107/1561) |
1 entry |
ENSG00000177084 |
POLE |
small intestinal adenocarcinoma |
missense_variant |
14.29% (3/21) |
1 entry |
ENSG00000177084 |
POLE |
prostate adenocarcinoma |
sequence_alteration |
1.582% (34/2149) |
1 entry |
ENSG00000177084 |
POLE |
breast adenosis |
missense_variant |
16.67% (2/12) |
1 entry |
ENSG00000177084 |
POLE |
breast carcinoma |
missense_variant |
1.062% (16/1506) |
4 entries |
ENSG00000177084 |
POLE |
breast ductal adenocarcinoma |
missense_variant |
2.868% (46/1604) |
1 entry |
ENSG00000177084 |
POLE |
esophageal adenocarcinoma |
missense_variant |
3.473% (19/547) |
2 entries |
ENSG00000177084 |
POLE |
hepatocellular carcinoma |
missense_variant |
1.826% (18/986) |
2 entries |
ENSG00000177084 |
POLE |
oral squamous cell carcinoma |
missense_variant |
3.358% (9/268) |
5 entries |
ENSG00000177084 |
POLE |
Merkel cell skin cancer |
missense_variant |
4.255% (4/94) |
2 entries |
ENSG00000177084 |
POLE |
prostate carcinoma |
missense_variant |
1.408% (6/426) |
3 entries |
ENSG00000177084 |
POLE |
skin melanoma |
missense_variant |
3.534% (41/1160) |
6 entries |
ENSG00000177084 |
POLE |
prostate carcinoma |
sequence_alteration |
1.408% (6/426) |
1 entry |
ENSG00000177084 |
POLE |
dedifferentiated chondrosarcoma |
missense_variant |
12.5% (2/16) |
2 entries |
ENSG00000177084 |
POLE |
small cell lung carcinoma |
stop_gained |
2.935% (13/443) |
2 entries |
ENSG00000177084 |
POLE |
Ovarian Endometrioid Adenocarcinoma |
stop_gained |
14.1% (32/227) |
1 entry |
ENSG00000177084 |
POLE |
Merkel cell skin cancer |
sequence_alteration |
4.255% (4/94) |
1 entry |
ENSG00000177084 |
POLE |
small cell lung carcinoma |
missense_variant |
2.935% (13/443) |
4 entries |
ENSG00000177084 |
POLE |
nasopharyngeal squamous cell carcinoma |
missense_variant |
1.667% (3/180) |
2 entries |
ENSG00000177084 |
POLE |
melanoma |
stop_gained |
13.1% (19/145) |
1 entry |
ENSG00000177084 |
POLE |
anaplastic astrocytoma |
missense_variant |
2.273% (3/132) |
3 entries |
ENSG00000177084 |
POLE |
lung adenocarcinoma |
sequence_alteration |
3.073% (78/2538) |
3 entries |
ENSG00000177084 |
POLE |
lobular breast carcinoma |
missense_variant |
1.695% (4/236) |
1 entry |
ENSG00000177084 |
POLE |
esophageal squamous cell carcinoma |
missense_variant |
1.462% (10/684) |
2 entries |
ENSG00000177084 |
POLE |
pancreatic ductal adenocarcinoma |
missense_variant |
1.604% (27/1683) |
3 entries |
ENSG00000177084 |
POLE |
Brain Stem Glioblastoma |
conservative_inframe_deletion |
1.786% (1/56) |
1 entry |
ENSG00000177084 |
POLE |
pancreatic neuroendocrine tumor |
missense_variant |
2.542% (6/236) |
1 entry |
ENSG00000177084 |
POLE |
adrenal cortex carcinoma |
sequence_alteration |
1.058% (2/189) |
1 entry |
ENSG00000177084 |
POLE |
gastric intestinal type adenocarcinoma |
sequence_alteration |
5.882% (5/85) |
1 entry |
ENSG00000177084 |
POLE |
follicular thyroid carcinoma |
missense_variant |
2.899% (2/69) |
1 entry |
ENSG00000177084 |
POLE |
Ovarian Small Cell Carcinoma |
missense_variant |
33.33% (1/3) |
1 entry |
ENSG00000177084 |
POLE |
B-cell acute lymphoblastic leukemia |
sequence_alteration |
0.9009% (1/111) |
1 entry |
ENSG00000177084 |
POLE |
Invasive Breast Carcinoma |
frameshift_variant |
4.348% (2/46) |
1 entry |
ENSG00000177084 |
POLE |
head and neck squamous cell carcinoma |
sequence_alteration |
0.9539% (6/629) |
1 entry |
ENSG00000177084 |
POLE |
gastric adenocarcinoma |
conservative_inframe_deletion |
3.875% (31/800) |
1 entry |
ENSG00000177084 |
POLE |
papillary renal cell carcinoma |
missense_variant |
0.2584% (1/387) |
1 entry |
ENSG00000177084 |
POLE |
esophageal squamous cell carcinoma |
sequence_alteration |
1.462% (10/684) |
1 entry |
ENSG00000177084 |
POLE |
bronchoalveolar adenocarcinoma |
sequence_alteration |
4.545% (1/22) |
1 entry |
ENSG00000177084 |
POLE |
bile duct adenocarcinoma |
sequence_alteration |
1.12% (7/625) |
1 entry |
ENSG00000177084 |
POLE |
Signet Ring Cell Gastric Adenocarcinoma |
missense_variant |
33.33% (1/3) |
1 entry |
ENSG00000177084 |
POLE |
thyroid carcinoma |
sequence_alteration |
2.808% (26/926) |
1 entry |
ENSG00000177084 |
POLE |
anaplastic oligodendroglioma |
stop_gained |
2.247% (2/89) |
1 entry |
ENSG00000177084 |
POLE |
female breast carcinoma |
missense_variant |
0.3546% (1/282) |
1 entry |
ENSG00000177084 |
POLE |
acute myeloid leukemia |
frameshift_variant |
0.7931% (11/1387) |
1 entry |
ENSG00000177084 |
POLE |
urothelial carcinoma |
stop_gained |
10.47% (9/86) |
1 entry |
ENSG00000177084 |
POLE |
adenosquamous lung carcinoma |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000177084 |
POLE |
Invasive Breast Carcinoma |
missense_variant |
4.348% (2/46) |
1 entry |
ENSG00000177084 |
POLE |
colorectal adenoma |
sequence_alteration |
7.143% (1/14) |
1 entry |
ENSG00000177084 |
POLE |
glioma |
sequence_alteration |
0.2793% (2/716) |
1 entry |
ENSG00000177084 |
POLE |
polycythemia vera |
missense_variant |
0.9346% (1/107) |
1 entry |
ENSG00000177084 |
POLE |
follicular thyroid carcinoma |
sequence_alteration |
2.899% (2/69) |
1 entry |
ENSG00000177084 |
POLE |
esophageal adenocarcinoma |
stop_gained |
3.473% (19/547) |
1 entry |
ENSG00000177084 |
POLE |
papillary thyroid carcinoma |
stop_gained |
0.818% (4/489) |
1 entry |
ENSG00000177084 |
POLE |
Extraskeletal Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor |
missense_variant |
3.03% (1/33) |
1 entry |
ENSG00000177084 |
POLE |
Gastrointestinal stromal tumor |
missense_variant |
0.6757% (1/148) |
1 entry |
ENSG00000177084 |
POLE |
Pleural Epithelioid Mesothelioma |
missense_variant |
0.5025% (1/199) |
1 entry |
ENSG00000177084 |
POLE |
Mantle cell lymphoma |
missense_variant |
1.887% (1/53) |
1 entry |
ENSG00000177084 |
POLE |
non-small cell lung carcinoma |
conservative_inframe_deletion |
5.319% (10/188) |
1 entry |
ENSG00000177084 |
POLE |
Central Nervous System Lymphoma |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000177084 |
POLE |
metaplastic breast carcinoma |
sequence_alteration |
1.613% (1/62) |
1 entry |
ENSG00000177084 |
POLE |
pancreatic ductal adenocarcinoma |
stop_gained |
1.604% (27/1683) |
1 entry |
ENSG00000177084 |
POLE |
diffuse gastric adenocarcinoma |
missense_variant |
1.22% (1/82) |
1 entry |
ENSG00000177084 |
POLE |
neoplasm |
missense_variant |
3.448% (1/29) |
1 entry |
ENSG00000177084 |
POLE |
nasopharyngeal squamous cell carcinoma |
sequence_alteration |
1.667% (3/180) |
1 entry |
ENSG00000177084 |
POLE |
rectal adenocarcinoma |
stop_gained |
3.551% (25/704) |
1 entry |
ENSG00000177084 |
POLE |
anaplastic oligodendroglioma |
missense_variant |
2.247% (2/89) |
1 entry |
ENSG00000177084 |
POLE |
Uveal Melanoma |
sequence_alteration |
0.7812% (1/128) |
1 entry |
ENSG00000177084 |
POLE |
renal cell carcinoma |
missense_variant |
1.493% (1/67) |
1 entry |
ENSG00000177084 |
POLE |
Endometrial Clear Cell Adenocarcinoma |
frameshift_variant |
3.226% (4/124) |
1 entry |
ENSG00000177084 |
POLE |
lung adenocarcinoma |
frameshift_variant |
3.073% (78/2538) |
1 entry |
ENSG00000177084 |
POLE |
colorectal adenoma |
missense_variant |
7.143% (1/14) |
1 entry |
ENSG00000177084 |
POLE |
adrenocortical adenoma |
missense_variant |
2.439% (1/41) |
1 entry |
ENSG00000177084 |
POLE |
Malignant Germ Cell Tumor |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000177084 |
POLE |
Sinonasal Undifferentiated Carcinoma |
missense_variant |
8.333% (1/12) |
1 entry |
ENSG00000177084 |
POLE |
skin carcinoma |
missense_variant |
3.846% (4/104) |
1 entry |
ENSG00000177084 |
POLE |
papillary thyroid carcinoma |
sequence_alteration |
0.818% (4/489) |
1 entry |
ENSG00000177084 |
POLE |
undifferentiated pleomorphic sarcoma |
missense_variant |
1.613% (1/62) |
1 entry |
ENSG00000177084 |
POLE |
ovarian clear cell adenocarcinoma |
missense_variant |
1.316% (1/76) |
1 entry |
ENSG00000177084 |
POLE |
Pleural Mesothelioma |
missense_variant |
0.7042% (1/142) |
1 entry |
ENSG00000177084 |
POLE |
embryonal rhabdomyosarcoma |
missense_variant |
1.163% (1/86) |
1 entry |
ENSG00000177084 |
POLE |
acute lymphoblastic leukemia |
missense_variant |
0.1458% (1/686) |
1 entry |
ENSG00000177084 |
POLE |
brain glioblastoma |
sequence_alteration |
1.092% (16/1465) |
1 entry |
ENSG00000177084 |
POLE |
bile duct adenocarcinoma |
stop_gained |
1.12% (7/625) |
1 entry |
ENSG00000177084 |
POLE |
hemangioblastoma |
missense_variant |
7.692% (1/13) |
1 entry |
ENSG00000177084 |
POLE |
Tracheal Squamous Cell Carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000177084 |
POLE |
nasal cavity and paranasal sinus carcinoma |
missense_variant |
4.348% (1/23) |
1 entry |
ENSG00000177084 |
POLE |
Mixed Lobular and Ductal Breast Carcinoma |
missense_variant |
1.639% (1/61) |
1 entry |
ENSG00000177084 |
POLE |
multiple myeloma |
missense_variant |
0.8333% (1/120) |
1 entry |
ENSG00000177084 |
POLE |
Prostate Small Cell Carcinoma |
missense_variant |
5.263% (1/19) |
1 entry |
ENSG00000177084 |
POLE |
salivary gland squamous cell carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000177084 |
POLE |
bladder transitional cell carcinoma |
sequence_alteration |
5.97% (28/469) |
1 entry |